Get notified when SRPT files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Securities Litigation (worsened) — The securities class action was amended to add a new plaintiff and defendant and extend the class period to November 3, 2025.
- Litigation Contingency Charge (new) — A new $39.0 million litigation contingency charge was recorded for a probable and estimable loss from patent litigation settlement.
Sarepta revenue falls 34.3% to $401.3M on ELEVIDYS label limits; net loss -$4.9M
Filed August 5, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 6, 2025 · ~1 min read
Key Changes
-
high
ELEVIDYS label now carries a boxed warning for liver injury and excludes non-ambulatory patients, cutting product revenue 36% to $328.7M.
MD&A: ELEVIDYS label verify on EDGAR → -
high
ESSENCE confirmatory trial for AMONDYS 45 and VYONDYS 53 missed its primary endpoint, putting their accelerated approvals at risk.
MD&A: ESSENCE trial verify on EDGAR → -
high
FDA keeps SRP-9003 on clinical hold and requires sirolimus data before accepting a BLA, delaying the LGMD program.
MD&A: SRP-9003 verify on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (ESTC 10-Q) is open in full — no account needed.
Partner
Trade SRPT commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify